Amylyx Pharmaceuticals, Inc.
AMLX
Ранг среди акций
#4401
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Цена акции
$28.50
Рыночная капитализация
$3.58B
Изменение (1 день)
4.29%
Изменение (1 год)
85.44%
Страна
US
Торговля Amylyx Pharmaceuticals, Inc. (AMLX)
Категория
Healthcare
Коэффициент P/S для Amylyx Pharmaceuticals, Inc. (AMLX)
Коэффициент P/S на October 2026 TTM: 0.00
Согласно последним финансовым отчетам и цене акций Amylyx Pharmaceuticals, Inc., текущий коэффициент P/S (TTM) составляет 0.00. В конце 2023 он составлял 2.60.
История P/S для Amylyx Pharmaceuticals, Inc. с 2019 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 2.95 | 13.43% |
| 2023 | 2.60 | -97.65% |
| 2022 | 110.55 | -96.99% |
| 2021 | 3.67K | 133.72% |
| 2020 | 1.57K | 119.38% |
| 2019 | 715.53 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
